# Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

> **NCT02568839** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Hatschek** · enrollment: 202 (actual)

## Conditions studied

- Early-Stage Breast Carcinoma
- HER-2 Positive Breast Cancer

## Interventions

- **DRUG:** docetaxel + trastuzumab sc + pertuzumab
- **DRUG:** trastuzumab emtansin

## Key facts

- **NCT ID:** NCT02568839
- **Lead sponsor:** Thomas Hatschek
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11
- **Primary completion:** 2019-02
- **Final completion:** 2029-02
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568839, "Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02568839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*